CD274 and neoplasm: The use of TILT-123 as a monotherapy and in combination with ACT has shown significant anti-tumoural activity, with modification of the tumour’s cytokine expression profile and increases in T cell infiltration, with compelling synergy with PD-L1 inhibition in a range of preclinical models [105,119,120,121,122,123].